{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:42:34Z","timestamp":1782564154526,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY024710"],"award-info":[{"award-number":["R01EY024710"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY001792"],"award-info":[{"award-number":["P30EY001792"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24EY033598"],"award-info":[{"award-number":["R24EY033598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY033622"],"award-info":[{"award-number":["R01EY033622"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY029426"],"award-info":[{"award-number":["R01EY029426"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drup.2026.101362","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:05:11Z","timestamp":1769713511000},"page":"101362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-3946","authenticated-orcid":false,"given":"Pankaj","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekhar D.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-6953","authenticated-orcid":false,"given":"Deepak","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.drup.2026.101362_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk9185","article-title":"Single-cell herpes simplex virus type 1 infection of neurons using drop-based microfluidics reveals heterogeneous replication kinetics","volume":"10","author":"Fredrikson","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2024.2425744","article-title":"An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application","volume":"15","author":"Su","year":"2024","journal-title":"Virulence"},{"issue":"7","key":"10.1016\/j.drup.2026.101362_bib3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41564-023-01405-y","article-title":"Modelling viral encephalitis caused by herpes simplex virus 1 infection in cerebral organoids","volume":"8","author":"Rybak-Wolf","year":"2023","journal-title":"Nat. Microbiol"},{"issue":"2","key":"10.1016\/j.drup.2026.101362_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14728214.2024.2339899","article-title":"Emerging drugs for the treatment of herpetic keratitis","volume":"29","author":"Kapoor","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drup.2026.101362_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem. Pharm."},{"issue":"3","key":"10.1016\/j.drup.2026.101362_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM198601163140303","article-title":"Vidarabine versus acyclovir therapy in herpes simplex encephalitis","volume":"314","author":"Whitley","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.drup.2026.101362_bib8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200\u2013500 CD4+ cells per cubic millimeter","volume":"333","author":"Eron","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.drup.2026.101362_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/QCO.0000000000000554","article-title":"Herpes simplex virus encephalitis update","volume":"32","author":"Stahl","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.drup.2026.101362_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro1855","article-title":"The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K\u2013Akt\u2013mTOR signalling pathway","volume":"6","author":"Buchkovich","year":"2008","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.drup.2026.101362_bib11","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1038\/s41467-021-26260-5","article-title":"mTORC2 confers neuroprotection and potentiates immunity during virus infection","volume":"12","author":"Suryawanshi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101362_bib12","author":"Johnson-Arbor","year":"2025","journal-title":"Doxorubicin StatPearls"},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2004.04.002","article-title":"Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization","volume":"32","author":"R\u016f\u017eena","year":"2005","journal-title":"J. Clin. Virol."},{"issue":"7","key":"10.1016\/j.drup.2026.101362_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdj132","article-title":"Antiviral prophylaxis in patients with haematological malignancies and solid tumours","volume":"17","author":"Sandherr","year":"2006","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.drup.2026.101362_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.drup.2026.101362_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00006-24","article-title":"The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis","volume":"37","author":"Antony","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"issue":"428","key":"10.1016\/j.drup.2026.101362_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5861","article-title":"An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye","volume":"10","author":"Jaishankar","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"48","key":"10.1016\/j.drup.2026.101362_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000630","article-title":"Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer","volume":"2","author":"Wallin","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"3\u20134","key":"10.1016\/j.drup.2026.101362_bib19","first-page":"164","article-title":"A., Herpes infections in breast cancer patients treated with adjuvant chemotherapy","volume":"71","author":"Masci","year":"2007","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03552-20","article-title":"Herpes simplex virus 1 manipulates host cell antiviral and proviral DNA damage responses","volume":"12","author":"Mertens","year":"2021","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2006.12.001","article-title":"HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein","volume":"1","author":"Orvedahl","year":"2007","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.drup.2026.101362_bib22","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3904\/kjim.2018.469","article-title":"Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies","volume":"35","author":"Hong","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.drup.2026.101362_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2024.e01978","article-title":"Disseminated herpes simplex virus type 1 infection manifested as extensive oral ulcers, pneumonitis, and ileo-colitis in a neutropenic patient post-chemotherapy","volume":"36","author":"Patamatamkul","year":"2024","journal-title":"IDCases"},{"key":"10.1016\/j.drup.2026.101362_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2255-8","article-title":"Herpes simplex virus-1 encephalitis induced by chemoradiotherapy and steroids in an esophageal cancer patient","volume":"16","author":"Saito","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.drup.2026.101362_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","article-title":"Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies","volume":"101","author":"Henze","year":"2022","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.drup.2026.101362_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15216540500079093","article-title":"The power and potential of doxorubicin\u2013DNA adducts","volume":"57","author":"Cutts","year":"2005","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.drup.2026.101362_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00958-13","article-title":"Epidermal growth factor receptor\u2013PI3K signaling controls cofilin activity to facilitate herpes simplex virus 1 entry into neuronal cells","volume":"5","author":"Zheng","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.drup.2026.101362_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-549","article-title":"Doxorubicin-enriched ALDHbr mouse breast cancer stem cells are treatable with oncolytic herpes simplex virus type 1","volume":"12","author":"Zhuang","year":"2012","journal-title":"BMC Cancer"},{"issue":"175","key":"10.1016\/j.drup.2026.101362_bib29","doi-asserted-by":"crossref","DOI":"10.3791\/62195","article-title":"Porcine corneal tissue explant to study the efficacy of herpes simplex virus-1 antivirals","author":"Yadavalli","year":"2021","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.drup.2026.101362_bib30","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41467-025-57965-6","article-title":"A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101362_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2026.101362_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.01.003","article-title":"Thymidine kinase and protein kinase in drug-resistant herpesviruses: heads of a Lernaean Hydra","volume":"37","author":"Topalis","year":"2018","journal-title":"Drug Resist. Updat"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:41:41Z","timestamp":1782099701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S1368764626000130"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101362","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101362"}}